Arvinas swings to FY26 Q2 net income of $169.4 million; revenue more than doubled to $249.7 million - ARVN News | RalliesArvinas swings to FY26 Q2 net income of $169.4 million; revenue more than doubled to $249.7 million
A
ARVN• Second-quarter results
- Arvinas posted Q2 net income of $169.4 million, swinging from a year-earlier loss; diluted EPS was $2.58.
- Revenue more than doubled to $249.7 million, driven by VEPPANU-related collaboration and licensing items, including Pfizer and Rigel agreements.
- R&D expense fell 23.32% to $52.6 million; GAAP G&A expense slipped 5.14% to $24 million.
- Cash, cash equivalents and marketable securities totaled $567.9 million at June 30, down $117.5 million from Dec. 31.
- VEPPANU won FDA approval then was out-licensed to Rigel; management flagged Phase 1 data updates for ARV-393, ARV-102, ARV-027 within 12 months.
AEHR
•
